Interleukin-12 enhances the antitumor activity of cytotoxic T lymphocytes against lung adenocarcinoma engrafted in severe combined immunodeficient mice

[1]  K. Yasumoto,et al.  Adoptive immunotherapy using specific cytotoxic T lymphocytes against human lung-cancer-engrafted severe combined immunodeficiency mice. , 2000, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[2]  S. Steinberg,et al.  Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.

[3]  K. Yasumoto,et al.  Effects of Interleukin‐12 on the Induction of Cytotoxic T Lymphocytes from the Regional Lymph Node Lymphocytes of Patients with Lung Adenocarcinoma , 1998, Japanese journal of cancer research : Gann.

[4]  G. Trinchieri,et al.  Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. , 1998, Cancer research.

[5]  K. Yasumoto,et al.  Autologous Tumor‐specific Cytotoxic T Lymphocytes in a Patient with Lung Adenocarcinoma: Implications of the Shared Antigens Expressed in HLA‐A24 Lung Cancer Cells , 1998, Japanese journal of cancer research : Gann.

[6]  K. Yasumoto,et al.  The Induction of Cytotoxic T Lymphocytes against HLA‐A Locus‐matched Lung Adenocarcinoma in Patients with Non‐small Cell Lung Cancer , 1997, Japanese journal of cancer research : Gann.

[7]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[8]  H. Takita,et al.  Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. , 1997, Cancer research.

[9]  T Nomura,et al.  The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. , 1997, Cancer research.

[10]  K. Fujiwara,et al.  Antitumor Effects of 5′‐Deoxy‐S‐fluorouridine in Combination with Recombinant Human Interleukin 2 on Murine Colon Carcinoma 26 , 1997, Japanese journal of cancer research : Gann.

[11]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  K. Takeda,et al.  Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. , 1996, Journal of immunology.

[13]  K. Yasumoto,et al.  Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients , 1996, Cancer Immunology, Immunotherapy.

[14]  K. Takeda,et al.  Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. , 1996, Journal of immunology.

[15]  P. Disaia,et al.  Effects of cytokines combined with high‐dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule‐1 in human ovarian cancers , 1996, International journal of cancer.

[16]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[17]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[18]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Negrin,et al.  A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. , 1994, Journal of immunology.

[20]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[21]  K. Orita,et al.  The enhancement of cell surface ICAM-I and HLA class I antigens in human gastric cancer cell lines by IFN-gamma. , 1994, Acta medica Okayama.

[22]  B. Perussia,et al.  Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. , 1994, Cancer research.

[23]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[24]  M. Gately,et al.  Regulation of human cytolytic lymphocyte responses by interleukin-12. , 1992, Cellular immunology.

[25]  A. Shino,et al.  Antitumor Effect of Recombinant Human Interleukin‐2 on the Growth of Murine Hemangioendothelioma D14 in Nude Mice: Occurrence of Large Granular Cells in the Tumor , 1991, Japanese journal of cancer research : Gann.

[26]  S. Rosenberg,et al.  In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.